Phase 1

​

We are developing the combination of melphalan, BCNU, vitamin B12b, and vitamin C for the treatment of Stage IV cancers in patients with an inherited BRCA1, BRCA2, or PALB2 mutation. Cancers currently under consideration are pancreatic and breast cancer.

​

The treatment is designed to:

• Exploit known hypersensitivities of BRCA-mutated cancer cells to DNA crosslinking drugs such as melphalan.

• Overcome each of the known mechanisms of drug resistance to melphalan.

 

The clinical trial is being conducted at major medical centers in Boston and New York.

For more information, visit our clinical trial website, www.SharonTrial.com, and the trial listing on ClinicalTrials.gov.

​

 

Preclinical

​

We are developing a pipeline of drug candidates for Stage IV solid cancers, as well as for myeloma, leukemia, and lymphoma.

 

Our solid tumor drug candidates are designed to:

• Target cancer cells throughout the body.

• Kill or deactivate cancer cells.

• Avoid targeting healthy tissue.

• To be used in combination with other drugs to overcome multiple mechanisms of drug resistance.

 

Examples of cancers that could be treatable with our solid tumor drug candidates are:

• Gastric cancer

• Lung cancer

• Ovarian cancer

• Melanoma

• Colorectal cancer

• Brain cancer

• Eye cancer

• Bladder cancer

• Prostate cancer

 

We are developing a combination of drugs for the treatment of myeloma, leukemia, and lymphoma. The combination is designed to:

• Target cancer cells throughout the body.

• Deactivate a subpopulation of the cancer cells so that they are no longer cancerous and kill the rest of the cancer cells.

• Overcome multiple mechanisms of drug resistance.